Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus
By W. Dejnirattisai, P. Supasa, Wiyada Wongwiwat, A. Rouvinski, G. Barba-Spaeth, Thaneeya Duangchinda, A. Sakuntabhai, Van-Mai Cao-Lormeau, P. Malasit, F. Rey and 2 more. Nature Immunology, 2016
888 citations recorded by the source corpus.
Zika virus (ZIKV) was discovered in 1947 and was thought to lead to relatively mild disease. The recent explosive outbreak of ZIKV in South America has led to widespread concern, with reports of neurological sequelae ranging from Guillain Barré syndrome to microcephaly. ZIKV infection has occurred in areas previously exposed to dengue virus (DENV), a flavivirus closely related to ZIKV. Here we investigated the serological cross-reaction between the two viruses. Plasma immune to DENV showed substantial cross-reaction to ZIKV and was able to drive antibody-dependent enhancement (ADE) of ZIKV infection. Using a panel of human monoclonal antibodies (mAbs) to DENV, we showed that most antibodies that reacted to DENV envelope protein also reacted to ZIKV. Antibodies to linear epitopes, including the immunodominant fusion-loop epitope, were able to bind ZIKV but were unable to neutralize the virus and instead promoted ADE. Our data indicate that immunity to DENV might drive greater ZIKV replication and have clear implications for disease pathogenesis and future vaccine programs for ZIKV and DENV.
Subfields: Parasitology, Public Health, Environmental and Occupational Health
View Paper: https://www.semanticscholar.org/paper/e046535f45150e003683cdadf49d321a2280b9ab
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- T. Pierson
- Michael S. Diamond
- Justin M. Richner
- S. Himansu
- Kimberly A. Dowd
- Vanessa Salazar
- S. Shresta
- William W Tang
Citations in the corpus
- Nucleic acid detection with CRISPR-Cas13a/C2c2 (2017, neutral): “SHERLOCKdetected viral particles down to 2 aM and could discriminate between ZIKV and DENV (Fig.”
- Modified mRNA vaccines protect against Zika virus infection (2017, positive): “…the absence of the FL results in a change in the display of neutralizing epitopes; or (c) the mutation of the FL in ZIKV SVPs prevents induction of neutralizing antibodies that bind epitopes proximal to the FL, as observed with EDE antibodies (Barba-Spaeth et al., 2016; Dejnirattisai et al., 2016).”